Assessment of global cardiovascular risk and risk factors in Portugal according to the SCORE® model

被引：5
作者：
De Oliveira Martins S. [1 ,2 ]
Serra E Silva P. [3 ,4 ]
Papoila A.L. [5 ]
Caramona M. [6 ]
Foppe Van Mil J.W. [7 ]
Cabrita J. [1 ,2 ]
机构：
[1] Faculdade de Farmácia, Universidade de Lisboa, Lisboa 1649-003, Av. Professor Gama Pinto
[2] IMed.UL, Lisbon
[3] Faculty of Medicine, University of Coimbra, Coimbra
[4] Portuguese Foundation of Cardiology, Lisbon
[5] Faculty of Medical Sciences, U. Nova, Lisbon
[6] Faculty of Pharmacy, University of Coimbra, Coimbra
[7] Van Mil Consultancy, Zuidlaren
来源：
Journal of Public Health | 2008年 / 16卷 / 5期
关键词：
Cardiovascular risk estimation; Cardiovascular risk factors; Epidemiology; Portugal; SCORE® risk chart;
D O I：
10.1007/s10389-008-0183-z
中图分类号：
学科分类号：
摘要：
Background/objective: Cardiovascular diseases (CVD) are the leading cause of mortality in European countries. This study aimed at estimating the 10-year risk of fatal CVD in Portuguese adults and to assess the prevalence of major cardiovascular risk factors, according to the SCORE® risk prediction system. Subjects and methods: A cross-sectional survey was carried out in 60 community pharmacies (CP) from October 2005 to January 2006 in a sample of CP users (≥40 and ≤65 years). Data were collected by patient interviews using a structured questionnaire applied by a trained pharmacist. Results: A total of 1,043 individuals were enrolled in the study (participation rate: 91%). The mean age was 53.7 years (SD: 7.1) with a ratio men/women of 0.68. The average risk in the sample was 1.94 (minimum 0, maximum 28, SD=2.69). About 20% of the studied adults were at high risk, of which 39.4% were asymptomatic. CV risk was significantly higher in the oldest age group and in men (p<0.05). The prevalence of main CV risk factors was: hypertension-54.8%; hypercholesterolemia-63.1%, diabetes-13.4%; smoking-10.4% and obesity-29.0%. About 1/3 of those asked had family history of premature CVD. Mean values of biochemical and clinical parameters were: systolic blood pressure (mmHg): 134.8±19.7; diastolic blood pressure (mmHg): 81.0±11.4; total cholesterol (mg/dl): 193.8±34.6; body mass index (kg/m2): 28.0±4.5. Conclusions: According to SCORE®, about one-fifth of the individuals was classified as high risk, and 7.7% was asymptomatic. CV risk was significantly higher in the oldest age group (55-65 years old) and in men (p<0.05). These results show a high prevalence of some risk factors, particularly hypertension and hypercholesterolemia. © 2008 Springer-Verlag.
引用
收藏
页码：361 / 367
页数：6
相关论文
共 26 条
[1]  
Amariles P., MacHuca M., Jimenez-Faus A., Silva-Castro M.M., Sabater D., Baena M.I., Et al., Cardiovascular risk: Components, evaluation and preventative interventions, Ars Pharmaceutica, 45, pp. 187-210, (2004)
[2]  
Atthobari J., Monster T.B., De Jong P.E., De Jong-Van Den Berg L.T., Prevention Study Group-The effect of hypertension and hypercholesterolemia screening with subsequent intervention letter on the use of blood pressure and lipid lowering drugs, Br J Clin Pharmacol, 57, pp. 328-336, (2004)
[3]  
Buitrago F., Canon-Barroso L., Diaz-Herrera N., Cruces-Muro E., Escober-Fernandez M., Serrano-Arias J.M., Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment, Rev Esp Cardiol, 60, pp. 139-147, (2007)
[4]  
Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., Et al., Estimation of ten-year of fatal cardiovascular disease in Europe: SCORE project, Eur Heart J, 24, pp. 987-1003, (2003)
[5]  
Costa J., Borges M., Oliveira E., Gouveia M., Vaz Carneiro A., Incidence and Prevalence of Hypercholesterolemia in Portugal: A systematic review, Part III. Rev Port Cardiol, 22, pp. 829-836, (2003)
[6]  
De MacEdo M.E., Lima M.J., Silva A.O., Alcantara P., Ramalhinho V., Carmona J., Prevalence, awareness, treatment and control of hypertension in Portugal. the PAP study, Rev Port Cardiol, 26, pp. 21-39, (2007)
[7]  
European guidelines on cardiovascular prevention in clinical practice, Eur J Cardiovasc Prev Rehabil, 10, SUPPL. 1, pp. 1-78, (2003)
[8]  
Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: Executive summary, Am J Clin Nutr, 68, pp. 899-917, (1998)
[9]  
Fornasini M., Brotons C., Sellares J., Martinez M., Galan M.L., Saenz I., Et al., Consequences of using different methods to access cardiovascular risk in primary care, Fam Pract, 23, pp. 28-33, (2006)
[10]  
Getz L., Sigurdsson J.A., Hetlevik I., Kirkengen A.L., Romundstad S., Holmen J., Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: Modelling study, Br Med J, 331, pp. 551-554, (2005)
123